A regulator has cleared a wearable sensor that reports both blood sugar and ketone readings from the same device. It is a measurement tool, not a treatment, and the practical value depends on who is using it and why.
Key takeaways
- A single wearable that measures both glucose and ketones combines two readings that previously required separate devices or a fingerstick blood test.
- Continuous glucose monitoring is an established technology, while continuous ketone sensing on the same platform is the newer element.
- Ketone levels matter most for people at risk of diabetic ketoacidosis, a serious complication that can develop quickly and is treated as a medical emergency.
- Regulatory authorisation means a device met a standard for its stated purpose; it is not a statement that the device suits every user or replaces medical advice.
- Anyone considering the device should confirm with a clinician what readings mean for their own condition, and what to do when a number falls outside the expected range.
What has actually been authorised
The subject here is a body-worn sensor that reports two things at once: an estimate of glucose levels and an estimate of ketone levels. Both are inferred from interstitial fluid, the fluid that sits between cells just under the skin, rather than from a blood sample. A small filament sits under the skin, a transmitter sits on the surface, and readings are sent to a phone or receiver at regular intervals.
Glucose monitoring in this form is familiar. Continuous glucose monitors, usually shortened to CGMs, have been sold for years and are used by many people with type 1 and type 2 diabetes. The new element is that the same sensor also tracks ketones, which until now generally meant a separate test: a fingerstick blood ketone meter, or a urine strip that changes colour.
Regulatory authorisation is narrower than it often sounds in headlines. It means a body reviewed evidence that the device performs as described for a defined intended use and a defined population. It does not mean the device is recommended for everyone, that it is covered by insurance or a health service, or that it is available immediately. The specific wording of any authorisation — which users, which claims, what warnings — is the part that determines how it can be sold and marketed, and that detail is what an interested reader should look up directly rather than take from summaries.
Why this is being discussed now
Attention follows the regulatory milestone. A first-of-its-kind clearance is a discrete, datable event, so it travels well across technology and health coverage even when the underlying science has been developing for years.
There is also a wider context. Wearable metabolic sensors have moved beyond clinical use into general consumer interest, with people without diabetes buying glucose monitors to observe how meals and exercise affect them. Ketone tracking has a parallel following among people who follow low-carbohydrate or ketogenic diets and want to confirm they are in a state of ketosis. A device that does both lands in the middle of a clinical need and a consumer trend at the same time, which is part of why the discussion is louder than the technical step alone would suggest.
The background a newcomer needs
Glucose is the body’s main circulating fuel. Insulin allows cells to take it up. When insulin is absent or insufficient, glucose accumulates in the blood while cells remain short of fuel.
Ketones are what the body produces when it burns fat for energy instead. This happens normally during fasting, prolonged exercise or a very low-carbohydrate diet, and at modest levels it is not dangerous. The problem arises when high glucose and high ketones occur together in someone with insufficient insulin. Ketones are acidic, and if they build up faster than the body can clear them the blood chemistry shifts. This is diabetic ketoacidosis, or DKA. It can develop over hours, and it requires urgent medical treatment.
That is why the two numbers are more useful together than apart. A high glucose reading alone does not distinguish between a manageable high and the start of DKA. A rising ketone level alongside it is the signal that changes the clinical picture. There is a further wrinkle: some diabetes medications can lead to ketoacidosis while glucose readings look close to normal, a pattern sometimes described as euglycaemic DKA. In that case, a glucose reading on its own is actively reassuring in a way it should not be.
Who this affects, and how
The clearest group is people with type 1 diabetes, who face the highest DKA risk and who already manage insulin dosing against continuously changing numbers. For them, ketone data that arrives automatically rather than requiring a decision to test could shorten the gap between a problem starting and being noticed. People with type 2 diabetes on certain medication classes are a second group, particularly given the euglycaemic pattern described above.
Carers and parents are affected indirectly. Much of the value of continuous monitoring lies in remote alerts, and adding a second measurement adds a second class of alert that someone has to interpret, often at night.
Then there are consumers without diabetes. Ketone readings are of interest to people tracking a ketogenic diet, and glucose readings to people curious about their responses to food. For this group the readings are informational rather than clinical, and the interpretive frameworks are thinner. What counts as a normal ketone level during a fast is not the same question as what counts as a dangerous one during illness, and the same number can mean different things in each context.
Finally, clinicians are affected by the volume. Every new continuous data stream produces readings between appointments that someone may be expected to review.
Where informed people disagree
The disagreements are less about whether the technology works and more about what should be done with it.
One argument concerns accuracy thresholds. Interstitial readings lag behind blood readings, and that lag matters more when a value is changing quickly — which is exactly the situation in developing ketoacidosis. How closely a continuous ketone reading tracks a blood ketone measurement during rapid change is a legitimate technical question, and the answer belongs in the device’s own performance data rather than in general commentary.
A second concerns non-clinical use. Some clinicians see broad consumer metabolic monitoring as useful feedback that encourages engagement with diet and activity. Others argue it produces anxiety over normal physiological variation, and that people without diabetes generally lack the training to distinguish a meaningful pattern from noise.
A third concerns cost and access. Continuous monitoring involves recurring consumable costs, and whether a combined sensor is funded by insurers or public health systems shapes who actually benefits. Reimbursement decisions typically follow authorisation by a considerable margin.
What this means in practice
If you are managing diabetes, the sensible step is a conversation with your care team rather than a purchase decision. Useful questions: does a ketone reading change my sick-day plan, at what value should I act, and does it replace or supplement the blood ketone meter I already have? Continuous devices are usually positioned as adjuncts to established testing rather than substitutes, and any confirmatory testing your clinician currently relies on should be assumed to remain in place unless they say otherwise.
If you are a general consumer, be clear about what you are buying. A ketone reading tells you something about fuel use; it does not measure fat loss, health or diet quality. Availability, price and prescription status are the practical constraints, and they vary by country.
For everyone, the operational detail matters as much as the sensor: wear duration, warm-up time, what the alerts do, whether the app works with your phone, and what happens when a sensor fails early.
What to watch next
Watch for the published intended-use statement and performance data, which set the boundaries of the claims. Watch for availability and pricing in individual markets, and for whether a prescription is required. Watch for reimbursement decisions, which determine real access more than authorisation does. Watch for guidance from diabetes professional bodies on how continuous ketone data should be used in sick-day rules and DKA protocols, since clinical guidance usually trails device availability. And watch for competing products, because a first authorisation in a category is normally followed by others.
Frequently asked questions
What is the difference between a glucose monitor and a ketone monitor?
A glucose monitor estimates the level of sugar circulating in the body, which is the main fuel most cells use. A ketone monitor estimates the level of ketones, which the body produces when it burns fat for energy instead. They describe different metabolic states. Traditionally these have been separate measurements, with glucose read continuously by a wearable sensor and ketones read from a fingerstick blood meter or a urine strip.
Why would someone need to measure both at the same time?
The combination is more informative than either reading alone. High glucose with rising ketones in someone short of insulin can indicate diabetic ketoacidosis, a medical emergency. High glucose without ketones is a different situation. There is also a pattern where ketoacidosis develops while glucose looks near normal, associated with certain diabetes medications, which a glucose reading alone would not flag.
Does regulatory authorisation mean the device is safe for everyone?
No. Authorisation means a regulator reviewed evidence that a device performs as described for a specific intended use and a specific group of users. It is not a general endorsement, a statement that the device suits every person, or a guarantee of any individual outcome. The authorisation document itself sets out who the device is for and what warnings apply, and that scope is what determines appropriate use.
Can people without diabetes use a device like this?
Whether a given device can be bought without a prescription depends on its authorised intended use and on local rules, which differ by country. Even where purchase is possible, the interpretive value is limited: reference ranges and clinical guidance are built around people managing diabetes. A reading that would prompt urgent action in one context may be an unremarkable consequence of fasting in another.
Does a wearable ketone sensor replace a blood ketone test?
Not automatically. Continuous sensors read interstitial fluid rather than blood, and readings can lag behind blood values when levels are changing quickly. Devices of this type are commonly positioned as an addition to existing testing rather than a replacement for it. Whether confirmatory blood testing remains necessary in a specific care plan is a question for the clinician who set that plan.
How much does continuous monitoring cost?
Pricing was not established at the point of authorisation and varies considerably by country, by whether a device is prescribed, and by whether insurers or a public health service cover it. The recurring cost of replacement sensors usually matters more over time than the initial purchase. Reimbursement decisions are made separately from regulatory authorisation and typically arrive later.
Sources and further reading
- The regulatory authority’s own device database and authorisation notices, which carry the intended-use statement and any conditions attached.
- Diabetes professional associations, for clinical standards on ketone testing, sick-day rules and management of ketoacidosis.
- Peer-reviewed diabetes technology journals, for validation studies comparing continuous sensor readings against blood measurements.
- General medical reference material from national health services, for background on ketones, glucose and diabetic ketoacidosis.
Surfaced from the hackernews signal “a medical device authorisation”. AI-assisted draft, editorially reviewed.
